Shots:

• Sandoz to get WW rights to distribute & commercialize proposed biosimilar natalizumab in all markets following its approval. Polpharma Biologics will be responsible for development- manufacturing and supply of proposed biosimilar natalizumab
• The focus of the agreement is to expand Novartis/Sandoz’s portfolio across small molecules- complex generics- biosimilars- and innovator therapies with the addition of proposed biosimilar natalizumab enabling patients to access patented and off-patent therapies
• Natalizumab is a mAb targeting adhesion molecule α4-integrin- the first-in-class therapy for the treatment of MS and is the fifth proposed biosimilar in-licensed by Sandoz in 9 months  

Click here to­ read full press release/ article | Ref: Novartis | Image: Behance